Healthy Volunteers
Conditions
Keywords
Inflammation, Vagus Nerve Stimulation
Brief summary
Persistent chronic inflammation is an important underlying event in multiple diseases including rheumatoid arthritis, inflammatory bowel diseases and type 2 diabetes. These disorders are characterized as inflammatory in part because of the important mediating role of pro-inflammatory cytokines in their pathogenesis. This study will investigate whether transcutaneous auricular electrical stimulation of the vagus nerve will affect and decrease the inflammatory cytokine response in healthy individuals.
Interventions
DEVICEVagus Nerve Stimulation
Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch of the vagus nerve.
Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
Sponsors
Northwell Health
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Age between 18-60 years, 2. Currently healthy with no medical problems 3. Able and willing to give written informed consent and comply with the requirements of the study protocol.
Exclusion criteria
1. History of any of the following: cardiac arrhythmia, coronary artery disease, autoimmune disease, chronic inflammatory disease, anemia, malignancy, depression, neurologic disease, diabetes mellitus, renal disease, malignancy, dementia, psychiatric illness including active psychosis, or any other chronic medical condition. 2. Family history of inflammatory disease 3. Treatment with an anti-cholinergic medication, including over the counter medications, 4. Implantable electronic devices such as pacemakers, defibrillators, hearing aids, cochlear implants or deep brain stimulators. 5. Current tobacco or nicotine user (to limit potential confounding effects of exposure to nicotine), 6. Chronic inflammatory disorders 7. Investigational drug and/or treatment during the 28 days or seven half-lives of the investigational drug prior to the start of study drug dosing (Day 0), whichever is the greater length of time, 8. Any condition which, in the opinion of the investigator, would jeopardize the subject's safety following exposure to a study intervention, 9. Pregnancy or lactation (Pregnancy status & lactation will be determined via self-report), 10. Implanted vagus nerve stimulator 11. Inability to comply with study procedures 12. Ear infection (otitis media or externa)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Lipopolysaccharide stimulated levels of TNF in whole blood. | 4 hours | Whole blood will be taken from patients and stimulated by lipopolysaccharide. Levels of TNF produced by the cells in the whole blood after 4 hours of incubation will be measured. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Lipopolysaccharide stimulated levels of cytokines such as IL-1, IL-6, IL-8, IL-10 and HMGB1 in whole blood. | 4 hours | Whole blood will be taken from patients and stimulated by lipopolysaccharide. Levels of cytokines such as IL-1, IL-6, IL-8, IL-10 and HMGB1 that are produced by the cells in the whole blood after 4 hours of incubation will be measured. |
| Percentage of subjects with treatment emergent adverse events | 1 hour | The percentage of participants with treatment emergent adverse events will be assessed using the NCI-CTAEversion4. |
Countries
United States
Outcome results
None listed